Physician profile
James Pang
NPI 1790279446
$5,373.32
in general payments reported to CMS, 2019-2025
28 companies · $1,246 in 2025
The $1,246 reported for 2025 was more than what 84% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $380 · 2022: $1,204 · 2023: $1,343 · 2024: $1,200 · 2025: $1,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,789.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,302.20 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $618.60 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals Lp | $591.68 | 2022-2025 | Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $405.30 | 2021-2025 | Verquvo, Steglatro, Belsomra |
| Bayer Healthcare Pharmaceuticals INC. | $357.41 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $342.93 | 2021-2025 | |
| Glaxosmithkline, LLC. | $277.21 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $213.22 | 2023-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $195.15 | 2022-2025 | Freestyle Libre 3, Mitraclip |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.42 | 2021-2025 | Jardiance |
| Boston Scientific Corporation | $141.00 | 2022-2023 | Watchman Access System |
| Amgen INC. | $109.03 | 2023-2025 | Repatha |
| Pfizer INC. | $103.65 | 2021-2025 | |
| Medtronic, INC. | $73.72 | 2025 | Minimed 780g |
| Amarin Pharma, INC. | $70.47 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $58.71 | 2021-2023 | Camzyos |
| Janssen Pharmaceuticals, INC | $57.59 | 2022-2024 | Xarelto |
| Exact Sciences Corporation | $48.10 | 2023 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $39.27 | 2022 | |
| Edwards Lifesciences Corporation | $38.80 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Ironwood Pharmaceuticals, INC | $32.40 | 2024 | |
| Xeris Pharmaceuticals, INC. | $30.07 | 2024 | Gvoke Hypopen |
| Ardelyx, INC. | $20.11 | 2024 | Ibsrela |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.00 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.87 | 2022 | |
| Alnylam Pharmaceuticals INC. | $14.58 | 2022 | |
| Astellas Pharma US INC | $11.75 | 2021 | |
| Axsome Therapeutics, INC. | $9.08 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Pang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.